Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Tislelizumab with DEB-BACE in Advanced NSCLC
NCT05380271Phase 2Not yet recruiting
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of anlotinib, tislelizumab in non-small cell lung cancer (NSCLC). Planned start Jul 2022; status: not yet recruiting.
02
Drugs
anlotinibtislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05380271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380271.